The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy
Study Details
Study Description
Brief Summary
In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Pregnant women with preeclampsia between 20-28 weeks (study group) Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia |
Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
|
| Healthy pregnant women between 20-28 weeks ( control group) Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group) |
Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women
The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
|
Outcome Measures
Primary Outcome Measures
- Comparison of the effects and composite results of cathepsin b and pentraxin 3 levels in pregnant women diagnosed with preeclampsia [12 months]
serum cathepsin b (nmoL pNA/mL) and serum pentraxin 3 (ng/ml) levels composite results on pregnant women diagnosed with preeclampsia
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Singleton pregnancy
-
Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
-
Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.
Exclusion Criteria:
-
Multiple pregnancies
-
Pregnant women who gave birth below 24 weeks of gestation
-
Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
-
Pregnant women with chromosomal or congenital anomalies in the fetus
-
Women with a known infective or autoimmune disease before pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nefise Nazlı YENIGUL | Bursa | Turkey | 16110 |
Sponsors and Collaborators
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2011-KAEK-25 2021/09-09